Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition
Neurobiology of Aging, ISSN: 0197-4580, Vol: 95, Page: 46-55
2020
- 34Citations
- 4Usage
- 41Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations34
- Citation Indexes34
- 34
- CrossRef24
- Usage4
- Abstract Views4
- Captures41
- Readers41
- 41
- Mentions1
- News Mentions1
- 1
Most Recent News
Impact of APOE-ε4 carriage on the onset and rates of neocortical Aβ-amyloid deposition.
Neurobiol Aging. 2020 Jun 10;95:46-55. Authors: Burnham SC, Laws SM, Budgeon CA, Doré V, Porter T, Bourgeat P, Buckley RF, Murray K, Ellis KA, Turlach BA, Salvado O, Ames D, Martins RN, Rentz D, Masters CL, Rowe CC, Villemagne VL, Alzheimer's Disease Neuroimaging Initiative, AIBL Research Group PubMed: 32750666 Submit Comment
Article Description
Neocortical Aβ-amyloid deposition, one of the hallmark pathologic features of Alzheimer's disease (AD), begins decades prior to the presence of clinical symptoms. As clinical trials move to secondary and even primary prevention, understanding the rates of neocortical Aβ-amyloid deposition and the age at which Aβ-amyloid deposition becomes abnormal is crucial for optimizing the timing of these trials. As APOE -ε4 carriage is thought to modulate the age of clinical onset, it is also important to understand the impact of APOE -ε4 carriage on the age at which the neocortical Aβ-amyloid deposition becomes abnormal. Here, we show that, for 455 participants with over 3 years of follow-up, abnormal levels of neocortical Aβ-amyloid were reached on average at age 72 (66.5–77.1). The APOE -ε4 carriers reached abnormal levels earlier at age 63 (59.6–70.3); however, noncarriers reached the threshold later at age 78 (76.1–84.4). No differences in the rates of deposition were observed between APOE -ε4 carriers and noncarriers after abnormal Aβ-amyloid levels had been reached. These results suggest that primary and secondary prevention trials, looking to recruit at the earliest stages of disease, should target APOE -ε4 carriers between the ages of 60 and 66 and noncarriers between the ages of 76 and 84.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0197458020301871; http://dx.doi.org/10.1016/j.neurobiolaging.2020.06.001; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85088976028&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/32750666; https://linkinghub.elsevier.com/retrieve/pii/S0197458020301871; https://ro.ecu.edu.au/ecuworkspost2013/8774; https://ro.ecu.edu.au/cgi/viewcontent.cgi?article=9780&context=ecuworkspost2013; https://dx.doi.org/10.1016/j.neurobiolaging.2020.06.001
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know